Exhibit 99.1 GLOBAL PARTNERS LP 800 South Street, Suite 500 P.O. Box 9161 Waltham MA 02454-9161 FOR IMMEDIATE RELEASE Contacts: Gregory B. Hanson Sean T. Geary Chief Financial Officer Chief Legal Officer and Secretary Global Partners LP Global Partners LP (781) 894-8800 (781) 894-8800 Global Partners Reports Second-Quarter 2024 Financial Results Waltham, Mass., August 7, 2024 – Global Partners LP (NYSE: GLP) ("Global" or the "Partnership") today reported financial results for the second quarter ended June 3 ...

MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new preclinical data demonstrating the synergistic effect of its lead compound, buntanetap, when combined with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide (Trulicity®) in a mouse model of Alz ...

Hims & Hers stock has been surging since May, but has its valuation gotten too rich? Healthcare stocks don't have to be making weight loss drugs to be hot buys due to the rising demand for glucagon-like peptide 1 (GLP-1) treatments. A good example of that is Hims & Hers Health (HIMS -12.85%). Up more than 140% this year, the telehealth company has been a hot buy with investors not only for its impressive growth but also for its ability to help connect patients with GLP-1 drugs. However, the company's strate ...

Patients who received liraglutide had an 18% slower decline in cognitive function after one year of treatment compared to those who received the placebo. Researchers presented the results on Tuesday at the Alzheimer's Association International Conference in Philadelphia, the world's largest meeting for dementia research. Brian B. Bettencourt | Toronto Star | Getty Images Notably, existing research shows that GLP-1s do not bring the risk of brain swelling and bleeding, two side effects that have been linked ...

Jacob Wackerhausen/iStock via Getty Images Therefore, it could end up being that this recombinant protein from Biohaven could have a synergistic effect with current treatment options. This is possible because of the mechanism of action of this drug compared to the other approved ones. In essence, taldefgrobep alfa is a myostatin inhibitor and its goal is to knock down the signaling of myostatin itself. This is important, because overactive myostatin activation inhibits muscle growth. Thus, the mechanism of ...

1. GZR18 injection is an investigational drug and has not yet been approved in China. In this study, the bi-weekly GZR18 injections were generally safe and well tolerated, consistent with the known safety signals of GLP-1 receptor agonists. The most common adverse events were gastrointestinal reactions, most of which were mild to moderate in severity, comparable to other GLP-1 RAs. In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked second overall and first am ...

Hims & Hers Health (NYSE:HIMS) has slipped back down below $20 after the initial excitement over access to a GLP-1 drug solution has worn off. The online health Source: Finviz Since announcing Q1'24 results in early May, Hims has seen some dramatic news. The online health provider announced the availability of a compound version of Novo Nordisk's (NVO) weight loss medication, and a short report from Hunterbrook Media questioned the business practices of the company. NEW, BIG INVESTIGATION: I felt like death ...

Cautionary Note Regarding Forward-Looking Statements 1 Year-Two Real-World Analysis of Glucagon-Like Peptide-1 Agonist (GLP-1) Obesity Treatment Adherence and Persistency, Prime Therapeutics/Magellan RX Management, 2024 NEW YORK, July 16, 2024 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today a new contract with a national employer to provide its cardiometabolic solution with integrated support for GLP-1s to employees b ...

But which one is a better stock to buy right now? Join me in analyzing each, and we'll figure it out together. Long story short, the data suggest that its molecule could lead to significantly faster weight loss than the medicines currently being sold by Eli Lilly as well as Novo Nordisk, and with a comparable side effect profile. Study participants lost, on a placebo-adjusted basis, an average of 13.1% of their weight after just 13 weeks of treatment. The cash cushion is also likely sufficient for it to rec ...

LLY $918.00 52-Week Range $434.34 $928.60 P/E Ratio 135.20 By all accounts, Eli Lilly's Tirzepatide, the active ingredient in Mounjaro and Zepbound, is superior on paper to Semaglutide, the active ingredient in Ozempic and Wegovy, because it targets two hormones compared to one. However, currently in Phase 2 clinical trials, its secret weapon for weight loss targets three hormones as the ultimate triple threat. Eli Lilly operates in the medical sector, facing competition from upcoming GLP-1 contenders from ...